The Food and Drug Administration approved a controversial drug meant to increase women’s desire for sex, a treatment that has rekindled a debate over the limits of medicine when it comes to human sexuality.

The drug, called Vyleesi, is an under-the-skin injection women take before sex. It’s approved for women with hypoactive sexual desire disorder, or HSDD, which is defined as a distressing loss of interest in sex.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • 1200 women participated in 2 Phase 3 Trials..80% of those women wanted to continue use of Vyleesi after the trials were concluded. As for the side effects, there is a lot of misrepresentation about the severity of those being reported today. The nausea was mostly transient and did not occur after the first dose in most cases. Vyleesi was well received by almost all of the participants and dropouts from the trial were around 8%.

  • Consumers injecting themselves is a huge roadblock for anything but a life-saving medicine like insulin. Maybe Vyleesi could be provided in an intranasal dosage form? Absorption through the intranasal route can cross the blood-brain barrier.

    • The initial clinical trials involved dosing via the intranasal method. Some test subjects experienced severe spikes in blood pressure and the FDA suspended the trial. The delivery method was revised to injection to mitigate the blood pressure issue and the clinical trials resumed.

    • The response from the study participants concerning the auto-injector was fairly positive though. Granted, their sentiment as people desperate enough to sign up for a clinical trial might not reflect that of the patient populace as a whole, but I think investors’ worries about this are probably excessive. My understanding is that the auto-injector is relatively simple and painless.

      “Regardless of treatment, the majority of participants (62.4%) rated their overall experience with the autoinjector as “very good” or “excellent,” and most participants (86.8%) reported that administering the study medication was “easy.” Slightly more participants preferred an on-demand injection over a daily pill.”

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy